Glenmark Pharmaceuticals Ltd said its Swiss arm has entered into an exclusive licensing agreement with Lotus International Pte Ltd for commercialising its innovative nasal spray Ryaltris in Singapore, Hong Kong and Vietnam.

• Nestle India Stocks Gained 3% on Q4FY24 Business and Financial Updates
• Rail Vikas Nigam Shares Gain 3% on Securing Project Worth Rs 239 Crore 
• Macrotech Shares Slump 4% on Weak Q4 Report 
• RITES Shares Gain 2% on Signing MoU for Rail Infrastructure Projects
• Stocks Under F&O Ban: Aditya Birla Fashion, Hindustan Copper, and Others

Under the agreement signed between Glenmark Specialty SA and the wholly-owned subsidiary of Lotus Pharmaceutical Co, Ltd (Lotus), Glenmark will be responsible for the manufacturing and supply of Ryaltris.

On the other hand Lotus will be responsible for its commercialization subject to receipt of regulatory approvals, in these markets, the company said in a statement.